Art. -Nr.: HY-A0168

Regadenoson

(Synonyms: CVT-3146)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.83%
CAS. Nr.: 313348-27-5
Formel: C₁₅H₁₈N₈O₅
Molecular Weight:390.35

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Regadenoson Chemical Structure

CAS. Nr.: 313348-27-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Alle Adenosine Receptor Isoform-spezifische Produkte anzeigen :

In Vivo

Regadenoson (0.1, 0.175, 0.25, 0.5, 1.0, 2.5, 5 μg/kg; p.i.v.; single) increases coronary blood flow (CBF) and decreases in mean coronary resistance in a dose-dependent manner, in awake dogs^[1].
? Regadenoson (2.5 μg/kg; p.i.v.; single in 30 s) increases blood flow of coronary in awake dogs^[1].
? Regadenoson (0.5 μg/kg; i.v.; single; 60 or 90 min after Temozolomide administration) promotes Temozolomide delivery to CNS of rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mongrel dogs (23-27 kg)^[1]
Dosage:

0.1, 0.175, 0.25, 0.5, 1.0, 2.5, 5 µg/kg
Administration:

Peripheral intravenous injection; single.
Result:

Increased mean CBF (coronary blood flow) in a dose-dependent manner, with an ED₅₀ of 0.34 µg/kg and resulted in a maximal increase of 154 mL/min from baseline (45 mL/min).
Caused a dose-dependent decrease in mean coronary resistance with a maximal decrease of 73 and 75 % at 2.5 and 5 µg/kg, respectively.

Animal Model:

Mongrel dogs (23-27 kg)^[1]
Dosage:

2.5 µg/kg
Administration:

Peripheral intravenous injection; single in 30 s.
Result:

Reached 84% of the peak reactive hyperemia flow following a 20-s-long coronary occlusion (201 mL/min).

Animal Model:

Female F344 rats (150-170 g)^[2]
Dosage:

0.5 µg/kg
Administration:

Intravenous injection; single (60 or 90 min after Temozolomide administration)
Result:

Increaseed levels of Temozolomide by 60 % in normal brain without affecting plasma concentrations.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 313348-27-5
Appearance Solid
Molecular Weight 390.35
Formel C₁₅H₁₈N₈O₅
Color White to off-white
SMILES

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(N=C2)C(N)=NC(N4C=C(C=N4)C(NC)=O)=N3)O1
Synonyms

CVT-3146
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

J Cell Commun Signal

Lactate drives CD38 signaling to promote Epithelial-Mesenchymal Transition through Snail induction in non-small cell lung cancer cells. [Abstract]

2024 Feb 14;18(1):e12018. PMID: 38545257
Turk J Med Sci

Contribution of adenosine A2A receptor agonist and antagonist on ovarian ischemia/reperfusion injury in rats. [Abstract]

2025 Dec 31;56(1):364-376. PMID: 41816720
bioRxiv

Host GPCR-cAMP signaling balances Gαs and Gαi activity to control intracellular Brucella infection. [Abstract]

2026 Jan 6:2026.01.06.697936. PMID: 41542404

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (128.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5618 mL

12.8090 mL

25.6180 mL

5 mM

0.5124 mL

2.5618 mL

5.1236 mL

10 mM

0.2562 mL

1.2809 mL

2.5618 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Trochu JN, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003 Jan;41(1):132-9. [Content Brief]

[2]. Jackson S, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126(3):433-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5618 mL	12.8090 mL	25.6180 mL	64.0451 mL
	5 mM	0.5124 mL	2.5618 mL	5.1236 mL	12.8090 mL
	10 mM	0.2562 mL	1.2809 mL	2.5618 mL	6.4045 mL
	15 mM	0.1708 mL	0.8539 mL	1.7079 mL	4.2697 mL
	20 mM	0.1281 mL	0.6405 mL	1.2809 mL	3.2023 mL
	25 mM	0.1025 mL	0.5124 mL	1.0247 mL	2.5618 mL
	30 mM	0.0854 mL	0.4270 mL	0.8539 mL	2.1348 mL
	40 mM	0.0640 mL	0.3202 mL	0.6405 mL	1.6011 mL
	50 mM	0.0512 mL	0.2562 mL	0.5124 mL	1.2809 mL
	60 mM	0.0427 mL	0.2135 mL	0.4270 mL	1.0674 mL
	80 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8006 mL
	100 mM	0.0256 mL	0.1281 mL	0.2562 mL	0.6405 mL

Keywords

Regadenoson

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Regadenoson

GPCR/G Protein Compound Library

FDA-Approved Drug Library

CNS-Penetrant Compound Library

Small Molecule Immuno-Oncology Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Regadenoson

Alle Adenosine Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Regadenoson Related Classifications

Art. -Nr.: HY-A0168